secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silo Pharma, Inc. (SILO)
CIK:        0001514183
Form:       8-K
Filed at:   2023-03-27T23:59:59+00:00
Accession:  0001213900-23-022970
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silo Pharma files provisional patent for ketamine pain management (SP-26) targeting fibromyalgia.
--------------------------------------------------------------------------------

- Provisional patent titled 'Methods and Compositions for Pain Management' covers chronic pain including fibromyalgia.
- Fibromyalgia affects approximately 2% of the U.S. population; initially targeted indication for company drug SP-26.
- Company is working towards submitting an IND package to FDA under 505(b)(2) regulatory pathway for SP-26.
- CEO Eric Weisblum states patent supports multi-pronged strategy to advance SP-26 into the clinic.
- Silo Pharma holds over six issued and provisional patents in rare disease space.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1514183/000121390023022970/0001213900-23-022970-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1514183/000121390023022970/ea175769-8k_silopharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-022970

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer